Combination therapy
Combination therapy is the use of two or more therapeutic agents, treatment modalities, or biologically distinct interventions to address a disease simultaneously.
Combination therapy is the use of two or more therapeutic agents, treatment modalities, or biologically distinct interventions to address a disease simultaneously. The components may be administered together or in sequence and can act through complementary mechanisms, such as direct cytotoxicity, immunotherapy, inhibition of signaling pathways, antiviral activity, anticoagulation, or modulation of the tumor microenvironment. Combination therapy is commonly contrasted with monotherapy, in which a single intervention is used.
The intended effects of combination therapy may include additive or synergistic therapeutic efficacy, broader control of disease biology, and circumvention of treatment resistance. In cancer research, combinations may involve cytotoxic drugs, checkpoint inhibitors, targeted agents, antiangiogenic treatment such as bevacizumab, or agents directed at pathways involving vascular endothelial growth factor, apoptosis, ferroptosis, macrophage activity, or transforming growth factor signaling. Assessment of a combination may include tumor control, survival, toxicity, cell viability, and mechanistic assays such as flow cytometry. However, the biological interaction between components can vary substantially across diseases and treatment regimens; the literature represented here spans neurological disease, cancer, viral pneumonia, leukemia, and mathematical modeling rather than forming a single disease-specific therapeutic program.
- Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. PMID 42711364
- Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. PMID 42714605
- Allosteric Inhibitors of Erythromycin Resistance Methyltransferase Reverse Antibiotic Resistance. PMID 42720463
Where the papers sit
10 papers study combination therapy directly. Those 10 do not group into themes. The cluster spans antimicrobial resistance, cancer treatment, neuroprotection, viral pneumonia, amyotrophic lateral sclerosis, and analytical methods. Its papers share an interest in therapeutic interventions but show no common biological question or direction. They are no more alike than papers drawn from anywhere in the corpus. 1 paradigm shift follows.
Combination therapy can reverse established treatment resistance rather than merely improve responses in treatment-sensitive disease
The erythromycin-resistance methyltransferase study in MLSB-resistant clinical isolates, the CDK12/13-inhibition study in platinum-resistant epithelial ovarian cancer models, and the histidine-liposome study in PARP-inhibitor-resistant breast-cancer models each used combination therapy to restore sensitivity to an otherwise compromised treatment: allosteric Erm inhibition reopened access to standard antibiotics, CDK12/13 inhibition resensitized resistant ovarian-cancer models to platinum, and Liposome His resensitized PARP-inhibitor-resistant cells to olaparib. These findings replace the assumption that combination therapy primarily adds the effects of concurrently active agents with a resistance-focused role in which one treatment disables or exploits the mechanism of resistance to recover the activity of another 42720463Sep 42686681Sep 42287952Jun.
Recent Findings on combination therapy
Diverse Therapeutic Interventions: Combination regimens target resistance, immune dysfunction, and overlapping disease mechanisms across antimicrobial, oncologic, neurologic, and viral models. Erm inhibitors restored macrolide, lincosamide, and streptogramin B activity, while CDK12/13 inhibition and Liposome His resensitized platinum- and PARP inhibitor–resistant cancer cells 42720463Sep42686681Sep42287952Jun. Clinical cohorts also associated combination therapy with improved outcomes, including longer survival after targeted immunotherapy plus transarterial chemoembolization in borderline resectable hepatocellular carcinoma and higher response rates with triple-agent Trop-2 ADC therapy in pretreated metastatic triple-negative breast cancer 42015536Apr42714605Sep. Benefits depended on regimen and context: three-drug dexamethasone, heparin, and CoVR-MV therapy rescued aged hamsters with viral pneumonia, whereas single and dual therapies were insufficient, and metformin plus empagliflozin improved rotenone-induced Parkinsonism more than either monotherapy 42684552Sep42711364Sep. Mathematical modeling linked tumor control to treatment intensity and initial tumor burden, while validated spectrophotometric and chromatographic methods supported quality control for celecoxib–ciprofloxacin therapy 42562918Aug42624937Aug.
Written from 10 PubMed abstracts, each one cited by PMID above. Published: 2026-09-10. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.